IRIS
GREMESE, ELISA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
AS - Asia 6.349
NA - Nord America 4.759
SA - Sud America 1.113
EU - Europa 825
AF - Africa 105
OC - Oceania 10
Continente sconosciuto - Info sul continente non disponibili 1
Totale 13.162
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.548
SG - Singapore 4.028
CN - Cina 1.047
BR - Brasile 909
VN - Vietnam 526
HK - Hong Kong 209
IT - Italia 154
IN - India 114
GB - Regno Unito 105
DE - Germania 97
CA - Canada 90
AR - Argentina 74
BD - Bangladesh 72
MX - Messico 70
RU - Federazione Russa 70
FR - Francia 63
IQ - Iraq 55
FI - Finlandia 48
EC - Ecuador 39
JP - Giappone 39
CZ - Repubblica Ceca 36
IE - Irlanda 34
ID - Indonesia 33
SE - Svezia 32
NL - Olanda 31
PK - Pakistan 30
ZA - Sudafrica 30
MY - Malesia 29
PL - Polonia 25
UA - Ucraina 25
CO - Colombia 24
TR - Turchia 23
VE - Venezuela 22
NP - Nepal 19
ES - Italia 18
LT - Lituania 18
MA - Marocco 17
PH - Filippine 17
PY - Paraguay 14
AT - Austria 13
SA - Arabia Saudita 13
CL - Cile 12
NG - Nigeria 12
AZ - Azerbaigian 11
BE - Belgio 11
KE - Kenya 11
UZ - Uzbekistan 11
AE - Emirati Arabi Uniti 10
CR - Costa Rica 9
KR - Corea 9
AU - Australia 8
IL - Israele 8
KZ - Kazakistan 8
EG - Egitto 7
JO - Giordania 7
UY - Uruguay 7
CH - Svizzera 6
GT - Guatemala 6
HN - Honduras 6
JM - Giamaica 6
LV - Lettonia 6
PE - Perù 6
BO - Bolivia 5
DZ - Algeria 5
IR - Iran 5
RO - Romania 5
TN - Tunisia 5
TT - Trinidad e Tobago 5
DK - Danimarca 4
DO - Repubblica Dominicana 4
NI - Nicaragua 4
OM - Oman 4
SN - Senegal 4
TH - Thailandia 4
AL - Albania 3
ET - Etiopia 3
GR - Grecia 3
HR - Croazia 3
PA - Panama 3
SK - Slovacchia (Repubblica Slovacca) 3
AO - Angola 2
BG - Bulgaria 2
CG - Congo 2
CI - Costa d'Avorio 2
GE - Georgia 2
KG - Kirghizistan 2
KH - Cambogia 2
KW - Kuwait 2
MN - Mongolia 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
RS - Serbia 2
SI - Slovenia 2
SV - El Salvador 2
SY - Repubblica araba siriana 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BS - Bahamas 1
Totale 13.144
Salva come PNG Salva come JPEG
Città #
Singapore 1.619
San Jose 993
Ashburn 866
The Dalles 626
Dallas 405
Shanghai 287
Beijing 264
Ho Chi Minh City 200
Hong Kong 195
Santa Clara 148
Chandler 117
Hanoi 114
Los Angeles 99
New York 86
São Paulo 77
Boardman 71
Helsinki 47
Brooklyn 35
Rio de Janeiro 35
Dublin 33
London 32
Montreal 31
Assago 28
Chennai 28
Mexico City 28
Wilmington 28
Belo Horizonte 26
Buffalo 26
Chicago 26
Stockholm 26
Tokyo 26
Toronto 26
Frankfurt am Main 25
Orem 25
Brno 24
Curitiba 23
Da Nang 23
Warsaw 23
Paris 21
Milan 19
Amsterdam 18
Atlanta 18
Haiphong 18
Munich 18
Campinas 17
Phoenix 17
Denver 16
San Francisco 15
Baghdad 14
Johannesburg 14
Lahore 14
Princeton 14
Salvador 14
Brasília 13
Council Bluffs 13
Dhaka 13
Goiânia 13
Lawrence 13
Mumbai 13
Naples 13
New Delhi 13
Quito 13
Reston 13
Ankara 12
Boston 12
Houston 12
Olomouc 12
Baku 11
Biên Hòa 11
Brussels 11
Kuala Lumpur 11
Santo André 11
Seattle 11
Moscow 10
San Mateo 10
Tashkent 10
Charlotte 9
Hangzhou 9
Hải Dương 9
Manchester 9
Rome 9
Cape Town 8
Guarulhos 8
Kathmandu 8
Poplar 8
San José 8
São Bernardo do Campo 8
Asunción 7
Benin City 7
Betim 7
Bắc Ninh 7
Can Tho 7
Changsha 7
Guayaquil 7
Karachi 7
Kyiv 7
Nairobi 7
Piracicaba 7
Sorocaba 7
Valparaíso de Goiás 7
Totale 7.496
Salva come PNG Salva come JPEG
Nome #
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naive patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial 118
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 110
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 98
Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials 97
Allele *2 of the HS1,2A enhancer of the Ig regulatory region associates with rheumatoid arthritis 95
Access of arthritis patients to an early arthritis clinic in three different settings: the very early ra represents the best clinical and therapeutic opportunity to reach das remission. Quality indicators (QI) of the italian ministry of health program 92
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine 86
Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections 78
Systemic sclerosis myocarditis has unique clinical, histological and prognostic features: a comparative histological analysis. 77
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 75
Safety and efficacy of rituximab biosimilar (CT-P10) in systemic sclerosis: an Italian multicentre study 73
A multiparametric risk table for loss of clinical remission status in patients with rheumatoid arthritis: A starter study post-hoc analysis 71
Biologics use in SLE in 23 centers – data from the international registry for biologics in SLE 70
QT and QT dispersion intervals in long-standing and moderately active rheumatoid arthritis: results from a multicentre cross-sectional study 70
B cell depletion and a T cell-targeted therapy allows to control the sudden onset of diabetes and lupus, without steroids 70
Anti-LL37 Antibodies Are Present in Psoriatic Arthritis (PsA) Patients: New Biomarkers in PsA. 70
Circulating Human Collagen II-Reactive T Cell in Early Rheumatoid Arthritis Produce IL17. 67
The Role of Microrna-34 and Microrna-22 in Dendritic Cells and Monocyte Activation in Rheumatoid Arthritis 66
Peripheral blood B cells subsets in patients with systemic lupus erythematosus: correlation with disease activity and organ involvement 65
Cancer in connective tissue disease 65
A brief battery for the evaluation of cognitive deficits in italian SLE patients 65
An unusual lung involvement in scleroderma: lipoid pneumonia 65
CD19+ cells subsets (CD5, CD38 and CD23) in peripheral blood and synovial fluid of rheumatoid arthritis patients: relationship with disease activity and with auto-antibody levels 64
ZAP70 B Cells and Plasmablasts As Markers of Disease Activity and Remission in Systemic LUPUS Erythematosus Nephritis 64
Early Spondyloarthritis Clinic: Organizational Improvements in the Patient Journey 64
B-cell depletion in rheumatoid arthritis: searching for serologic and clinical baseline factors that could predict long-term efficacy 63
Synovial fluid-derived T helper 17 cells correlate with inflammatory activity in arthritis, irrespectively of diagnosis 63
The prognostic significance of the Birmingham Vasculitis Activity Score (BVAS) with systemic vasculitis patients transferred to the intensive care unit (ICU) 62
An autosomal recessive DNASE1L3-related autoimmune disease with unusual clinical presentation mimicking systemic lupus erythematosus 61
Is Citrullination Required for the Presence of Restricted Clonotypes Reacting With Type II Collagen? Comment on the Article by Chemin et al 61
Results of the classification criteria for cryoglobulinemic vasculitis validation study 61
Association of the 22 genotype of enhancer HS1,2A of the Ig heavy 3′ regulatory region with non response to DMARDS and response to rituximab in rheumatoid arthritis patients 61
Effectiveness of SB4 Transition from Originator Etanercept in Rheumatoid Arthritis and Axial Spondyloarthritis: A Subgroup Analysis from the BENEFIT Study 61
ACPA–IL-6 as the best biomarkers to differentiate early rheumatoid arthritis from undifferentiated arthritis: analysis of the diagnostic performance 61
[Class IV-G and IV-S lupus nephritis, interstitial infiltrates and prognosis: state of the art and unmet medical needs] 60
A brief battery for the evaluation of cognitive deficits in italian SLE patients 60
Alveolar haemorrhage in ANCA-associated vasculitis: Long-term outcome and mortality predictors 60
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: an IG-IBD study 60
Antineutrophil cytoplasmic autoantibodies (ANCA) positivity as a red flag of severe disease in lupus nephritis 59
MicroRNA-34a dependent regulation of AXL controls the activation of dendritic cells in inflammatory arthritis 59
ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature 59
Off-label use of rituximab for SLE in Europe: a comparison to patients treated with conventional immunosuppressive medications 58
The UltraSound-CLinical ARthritis Activity (US-CLARA) index: Properties of a new composite disease activity index for rheumatoid arthritis 58
Minimal disease activity in early and longstanding rheumatoid arthritis 58
Amplifying the concept of psoriatic arthritis: The role of autoimmunity in systemic psoriatic disease 58
Gene-gene interaction and early rheumatoid arthritis: effects on the response to therapy 58
Porphyromonas Gingivalis and the Pathogenesis of Rheumatoid Arthritis: Analysis of the Synovial Tissue and of Other Compartments 58
Early vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease 58
B-cell directed therapy in rheumatoid arthritis: predictive factors of efficacy and assessment of regeneration profile 58
Severe eosinophilic asthma and aspirin-exacerbated respiratory disease associated to eosinophilic gastroenteritis treated with mepolizumab: a case report 57
Adult onset Still's disease and pregnancy 57
Renal inflammatory infiltrate in lupus nephritis patients 57
Metabolic syndrome in autoimmune diseases: prevalence and relationship with the inflammatory burden 57
The body mass index: a determinant of remission in early rheumatoid arthritis 57
Anti-nucleosome antibodies: correlations with activity and chronicity disease indexes in systemic lupus erythematosus patients with renal involvement 57
Gut microbiota analysis in systemic sclerosis according to disease characteristics and nutritional status 56
Early Disease and Low Baseline Damage as Predictors of Response to Belimumab in Patients With Systemic Lupus Erythematosus in a Real-Life Setting 56
Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients 56
B cell activating factor (BAFF) and BAFF receptors: fakes and facts 55
ZAP-70 expression in B-cells during repopulation of peripheral blood following B-cell depletion in rheumatoid arthritis 54
Anti-nucleosome antibodies: correlations with activity and chronicity disease indexes in systemic lupus erythematosus patients with renal involvement 54
Early rheumatoid arthritis (ERA) differs from long-standing RA (LSRA) in circulating B cell subsets. changes according to disease activity under conventional therapy 53
Baseline shoulder ultrasonography is not a predictive marker of response to glucocorticoids in patients with polymyalgia rheumatica: A 12-month followup study 53
Fatigue in Covid-19 survivors: The potential impact of a nutritional supplement on muscle strength and function 53
Abatacept in the treatment of psoriatic arthritis: biological and clinical profiles (of the responders) 53
Measuring the T-cell down-regulation of TCR-zeta, ZAP-70 and CD28 in arthritis patients: An old tool for new biomarkers 53
Distribution of body mass index and metabolic syndrome in patients with inflammatory autoimmune diseases from a single italian centre 52
Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients 52
Validation Study Of The International Classification Criteria For The Cryoglobulinemic Vasculitis 51
Integrin alpha2bbeta3 gene polymorphism and the microvascular system in scleroderma 51
Response to Interleukin-1 Inhibitors in 140 Italian Patients with Adult-Onset Still's Disease: A Multicentre Retrospective Observational Study 51
Driving chronicity in rheumatoid arthritis: Perpetuating role of myeloid cells 51
Predictors, Features and Effects of First Biologic Switch in Rheumatoid Arthritis within GISEA register: Italian 10-Year Experience. 51
Adiposity, joint and systemic inflammation: the additional risk of having a metabolic syndrome in rheumatoid arthritis 51
IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy 50
Depression and Endothelial Dysfunction in Psoriatic Arthritis: Is There Any Possible Relationship? 50
Loss of α2-6 sialylation promotes the transformation of synovial fibroblasts into a pro-inflammatory phenotype in arthritis 50
Tocilizumab in the treatment of arthritis: response to therapy and evaluation of B cells subsets after 4 months treatment 49
The B side of rheumatoid arthritis pathogenesis 49
Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting (BeRLiSS-LN). Results from a large, nationwide, multicentric cohort 49
Obesity as a risk and severity factor in rheumatic diseases (autoimmune chronic inflammatory diseases) 49
Effects of l-Arginine Plus Vitamin C Supplementation on l-Arginine Metabolism in Adults with Long COVID: Secondary Analysis of a Randomized Clinical Trial 48
Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study 48
Definition of fibromyalgia severity: Findings from a cross-sectional survey of 2339 Italian patients 48
Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study results 48
Early Rheumatoid Arthritis (ERA) Has Lower Levels of Plasmablasts and Memory B Cells Compared to Long-Standing Rheumatoid Arthritis (LSRA) and Responds to Conventional Therapy with a Normalization of B Cell Subsets Abnormalities. 48
Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years 48
Chemerin and PEDF are metaflammation-related biomarkers of disease activity and obesity in rheumatoid arthritis 48
Balance between hepatocyte growth factor (HGF) and transforming growth factor (TGF-BETA1) in renal biopsies of patients with lupus nephritis 47
Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis 47
Immune-Guided Therapy of COVID-19 46
Synovial fluid-derived TH17 cells correlate with disease activity in arthritis, irrespective of diagnosis 46
Malnutrition in COVID-19 survivors: prevalence and risk factors 46
Clinical nephritis remission is influenced by hepatocyte growth factor (HGF) and transforming growth factor-β1 (TGFβ1) renal tubular expression more than interstitial cell infiltrate in systemic lupus erythematosus (SLE) patients 46
Comment on: Emergence of severe spondyloarthropathy-related entheseal pathology following successful vedolizumab therapy for inflammatory bowel disease 46
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor Inhibitors 45
Synovial B cells of rheumatoid arthritis express ZAP-70 which increases the survival and correlates with the inflammatory and autoimmune phenotype 45
CD19+ZAP70+ B cells value at baseline predicts response at T6 to BCDT (B cell depletion therapy). Recovery is mainly characterized by the appearance of naïve activated B cells and ZAP-70 positive B cells 45
The measurement of fibromyalgia severity: converting scores between the FIQR, the PSD and the FASmod 45
Circulating memory B cells characterize active nephritis instead activated naïve B cells are expanded in active articular involvement in patients with systemic lupus erythematosus (SLE) 45
Totale 5.949
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.000
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.000
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20214 0 0 0 0 0 0 0 0 0 0 0 4
2021/202229 1 0 1 6 0 1 1 3 3 5 4 4
2022/2023277 28 13 28 43 21 25 0 27 45 30 16 1
2023/2024726 11 13 54 15 1 32 18 9 5 7 19 542
2024/20253.279 181 27 136 64 58 271 173 176 705 800 347 341
2025/20269.114 1.220 618 470 621 355 458 2.546 362 501 778 719 466
Totale 13.486